Midday Report: Organovo (ONVO) Gains on May 13
Equities Staff Follow |Organovo Holdings Inc (NASDAQ: ONVO) has risen $0.16 (6.61%) and is currently sitting at $2.58, as of 11:52:26 est on May 13.
20,031 shares have been traded today.
The Company is down 11.68% over the last 5 days and shares lost 24.14% over the last 30 days.
Organovo expects its next earnings on 2022-06-14.
For technical charts, analysis, and more on Organovo visit the company profile.
About Organovo Holdings Inc
Organovo is an early-stage biotechnology company that is developing and utilizing highly customized 3D human tissues as dynamic models of healthy and diseased human biology for drug development. The company's proprietary technology is being used to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Organovo's advances include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs for selected therapeutic areas.
To get more information on Organovo Holdings Inc and to follow the company's latest updates, you can visit the company's profile page here: Organovo Holdings Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.
Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer